Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | PTGFR | P43088 | 3/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 5/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.51 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.51 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.51 |
| ▸ | SLCO2A1 | Q92959 | 2/20 | 0.51 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | PTGIR | P43119 | 2/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22168569 | 0.87 | MEN1 (0.73) | MEN1KMT2APTGFRTBXA2RALDH1A1 | |
| SCHEMBL2512105 | 0.87 | MEN1 (0.73) | MEN1KMT2APTGFRTBXA2RALDH1A1 | |
| SCHEMBL2512107 | 0.87 | MEN1 (0.73) | MEN1KMT2APTGFRTBXA2RALDH1A1 | |
| SCHEMBL25710278 | 0.87 | MEN1 (0.73) | MEN1KMT2APTGFRTBXA2RALDH1A1 | |
| SCHEMBL34165 | 0.87 | MEN1 (0.73) | MEN1KMT2APTGFRTBXA2RALDH1A1 | |
| SCHEMBL24726792 | 0.87 | MEN1 (0.73) | MEN1KMT2APTGFRTBXA2RALDH1A1 | |
| SCHEMBL10721021 | 0.86 | MEN1 (0.72) | MEN1KMT2APTGFRTBXA2RALDH1A1 | |
| SCHEMBL9037070 | 0.81 | MEN1 (0.65) | MEN1KMT2APTGFRTBXA2RALDH1A1 | |
| SCHEMBL11073045 | 0.78 | TBXA2R (0.62) | MEN1KMT2APTGFRTBXA2RALDH1A1 | |
| SCHEMBL16468503 | 0.78 | TBXA2R (0.62) | MEN1KMT2APTGFRTBXA2RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041839-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2024-02-08 | — | — | US | claimed |
| US-20230090578-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2023-03-23 | — | — | US | claimed |
| US-20200405694-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2020-12-31 | — | — | US | claimed |
| EP-3716973-A1 | METHODS OF INHIBITING TUMOR METASTASIS | Vanderbilt University (US) | 2020-10-07 | — | — | EP | claimed |
| CN-111432817-A | Method of inhibiting tumor metastasis | 凡德贝尔大学 | 2020-07-17 | — | — | CN | claimed |
| US-9994901-B2 | Pro-inflammatory mediators in diagnosis and treatment of chronic obstructive pulmonary disease | NATIONAL JEWISH HEALTH, A NON-PROFIT ORGANIZATION (US) | 2018-06-12 | — | — | US | claimed |
| US-20150051259-A1 | PRO-INFLAMMATORY MEDIATORS IN DIAGNOSIS AND TREATMENT OF PULMONARY DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2015-02-19 | — | — | US | claimed |
| WO-2014011273-A2 | PRO-INFLAMMATORY MEDIATORS IN DIAGNOSIS AND TREATMENT OF PULMONARY DISEASE | THE REGENTS OF THE UNIVERSITY OF COLORADO a body corporate of the state of colorado (US) | 2014-01-16 | — | — | WO | claimed |
| US-20130289121-A1 | PULMONARY DISEASE TREATMENT AND DIAGNOSIS BASED ON ARHGEF1 | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-10-31 | — | — | US | claimed |
| WO-2012097232-A1 | PULMONARY DISEASE TREATMENT AND DIAGNOSIS BASED ON ARHGEF1 | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2012-07-19 | — | — | WO | claimed |
| WO-2009089098-A1 | METHODS FOR THE TREATMENT OF CANCERS | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2009-07-16 | — | — | WO | claimed |
| US-6099834-A | Method for modulating eicosanoid mediated immune responses in arthropods | BOARD OF REGENTS UNIVERSITY OF NEBRASKA-LINCOLN (US) | 2000-08-08 | — | — | US | claimed |
| US-20240041839-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2024-02-08 | — | — | US | disclosed |
| US-20230090578-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2023-03-23 | — | — | US | disclosed |
| US-20200405694-A1 | METHODS OF INHIBITING TUMOR METASTASIS | VANDERBILT UNIVERSITY | 2020-12-31 | — | — | US | disclosed |
| EP-3716973-A1 | METHODS OF INHIBITING TUMOR METASTASIS | Vanderbilt University (US) | 2020-10-07 | — | — | EP | disclosed |
| US-20030109571-A1 | Thromboxane ligands without blood clotting side effects | ALLERGAN SALES, INC. | 2003-06-12 | — | — | US | disclosed |
| US-6462077-B1 | OXABICYLCO COMPOUNDS; OCULAR HYPOTENSION, HYPERTENSION, HEMORRHAGE, MYOCARDIAL ISCHEMIA, ANGINA PECTORIS, CORONARY CONTRACTION, CEREBROVASCULAR CONTRACTION AFTER SUBARACH-NOIDAL HEMORRHAGE, CEREBRAL HEMORRHAGE, ASTHMA | ALLERGAN, INC. | 2002-10-08 | — | — | US | disclosed |
| WO-2000066577-A2 | BRIGDED CYCLOALKANES AS THROMBOXANE LIGANDS WITHOUT BLOOD CLOTTING EFFECTS | ALLERGAN SALES, INC. (US) | 2000-11-09 | — | — | WO | disclosed |
| US-6099834-A | Method for modulating eicosanoid mediated immune responses in arthropods | BOARD OF REGENTS UNIVERSITY OF NEBRASKA-LINCOLN (US) | 2000-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240041839-A1 | METHODS OF INHIBITING TUMOR METASTASIS | TBXA2R, ADORA2B, ADORA2A | MEN1 1012/4885KMT2A 2296/4885PTGFR 7/4885 |
| US-20200405694-A1 | METHODS OF INHIBITING TUMOR METASTASIS | TBXA2R, ADORA2B, ADORA2A | MEN1 1012/4885KMT2A 2296/4885PTGFR 7/4885 |
| US-20230090578-A1 | METHODS OF INHIBITING TUMOR METASTASIS | TBXA2R, ADORA2B, ADORA2A | MEN1 1012/4885KMT2A 2296/4885PTGFR 7/4885 |
| US-20030109571-A1 | Thromboxane ligands without blood clotting side effects | OXER1, TBXA2R, CBR1 | MEN1 3453/4885KMT2A 3435/4885PTGFR 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.